Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117296 | 0.88 | AAK1 (0.65) | KITAAK1BTKITKGSK3A | |
| SCHEMBL7114155 | 0.88 | GSK3A (0.62) | KITAAK1BTKITKGSK3A | |
| SCHEMBL7116485 | 0.88 | AAK1 (0.60) | AAK1GSK3AGSK3B | |
| SCHEMBL7117585 | 0.87 | AXL (0.61) | NTRK1DYRK1AAAK1BTKITK | |
| SCHEMBL7051030 | 0.87 | ADORA1 (0.53) | AAK1BTKITKGSK3AGSK3B | |
| SCHEMBL7116630 | 0.86 | AAK1 (0.56) | NTRK1DYRK1AAAK1BTKITK | |
| SCHEMBL7118372 | 0.85 | CAMKK2 (0.50) | DYRK1AAAK1BTKITKGSK3A | |
| SCHEMBL7118788 | 0.85 | AAK1 (0.58) | NTRK1DYRK1AAAK1BTKITK | |
| SCHEMBL4301384 | 0.85 | NTRK1 (0.62) | KITNTRK1AAK1BTKITK | |
| SCHEMBL7116088 | 0.83 | SGK1 (0.54) | AAK1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003028724-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | claimed |
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| CN-101448827-A | Indole derivatives | ASTRAZENECA AB (SE) | 2009-06-03 | — | — | CN | disclosed |
| WO-2003028724-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | KIT 322/4885NTRK1 942/4885PIK3CA 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.